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INTRODUCTION {#ped412108-sec-0006}
============

*Mycoplasma pneumoniae* can cause upper respiratory infection, bronchitis, bronchiolitis, and pneumonia. To our knowledge, only one pediatric case report of *M. pneumoniae* bronchiolitis in a 17‐year‐old girl has been published.[1](#ped412108-bib-0001){ref-type="ref"} Although *M. pneumoniae* bronchiolitis is uncommon, acute *M. pneumoniae* bronchiolitis may progress into bronchiolitis obliterans (BO) in children.[2](#ped412108-bib-0002){ref-type="ref"} There are also reports of *M. pneumoniae* bronchiolitis‐associated restrictive BO in adults.[3](#ped412108-bib-0003){ref-type="ref"}, [4](#ped412108-bib-0004){ref-type="ref"}, [5](#ped412108-bib-0005){ref-type="ref"} Because BO has a major influence on a child\'s quality of life and is associated with *M. pneumoniae* bronchiolitis, early identification and treatment of *M. pneumoniae* bronchiolitis is important to prevent the development of BO. To this end, we herein report eight cases of *M. pneumoniae* bronchiolitis in children to enhance the understanding of this disorder.

METHODS {#ped412108-sec-0007}
=======

Patients {#ped412108-sec-0008}
--------

Eight patients diagnosed with *M. pneumoniae* bronchiolitis from February 2016 to July 2017 were included in this study. The diagnosis of *M. pneumoniae* bronchiolitis was based on high‐resolution computed tomography (HRCT) findings, including centrilobular nodules, branching linear opacities (tree‐in‐bud pattern), and bronchiolar wall thickening;[6](#ped412108-bib-0006){ref-type="ref"} a serum IgM‐specific anti‐Mycoplasma antibody titer of ≥ 1:160 in the acute phase or a four‐fold rise during convalescence; and negative bacterial cultures of the blood, sputum, and/or bronchoalveolar lavage fluid were also suggestive of bronchiolitis.

Data collection {#ped412108-sec-0009}
---------------

This was an observational and descriptive study. The medical records of all patients were retrospectively reviewed. We collected data on demographic characteristics, clinical presentations, physical examination findings, chest HRCT findings, atopic data, and treatment. We also gathered follow‐up information on all patients. The data of all eight patients are shown in Table [1](#ped412108-tbl-0001){ref-type="table"}.

###### 

Clinical data of eight patients diagnosed with *Mycoplasma pneumoniae* bronchiolitis

  No.   Gender   Age     Complaint                                       PE of lung                 MP‐IgM   Chest HRCT of MP‐bronchiolitis                                                          Personal history of atopic disease   Family history of atopic disease   Allergen test & total IgE                                         Systemic glucocorticoid (methylprednisolone)
  ----- -------- ------- ----------------------------------------------- -------------------------- -------- --------------------------------------------------------------------------------------- ------------------------------------ ---------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------
  1     M        3y10m   fever for 3 days, cough and wheeze for 2 days   moist rales and wheezing   1:160    bilateral and diffuse centrilobular nodules, ground glass                               asthma                               father AR                          house dust mite grade‐1, total IgE \> 200 IU/ml                   D4, 2mg/kg/day
  2     F        4y9m    fever for 5 days, cough and wheeze for 3 days   moist rales and wheezing   1:320    bilateral and diffuse centrilobular nodules, ground glass                               (--)                                 brother AR                         not done                                                          D10, 1 mg/kg/day (transfer from other hospital to our hospital on D10)
  3     M        5y2m    fever and cough for 9 days                      (--)                       1:320    bilateral and diffuse centrilobular nodules, patchy shadow                              AR                                   mother AD                          negative,total IgE \> 200 IU/ml                                   D9, 2 mg/kg/day
  4     M        5y11m   fever and cough for 7 days                      moist rales and wheezing   1:320    bilateral tree‐in‐bud, ground glass and patchy shadow                                   urticaria                            (--)                               not done                                                          D9, 2 mg/kg/day
  5     F        8y7m    fever, cough and wheeze for 14 days             moist rales and wheezing   1:320    bilateral centrilobular nodules, bronchial wall thickening                              eczema, asthma                       (--)                               mould grade‐4, house dust mite grade‐3, total IgE \> 200 IU/ml    no use
  6     M        5y10m   fever for 9 days, cough for 7 days              moist rales and wheezing   1:320    diffuse centrilobular nodules, small patchy within right lung                           (--)                                 mother asthma                      negative,total IgE \> 200 IU/ml                                   D9, 2 mg/kg/day
  7     M        6y      cough for 11 days, fever for 9 days             wheezing                   1:320    bilateral and diffuse centrilobular nodules, tree‐in‐bud and patchy shadow              (--)                                 (--)                               house dust mite grade‐3,cat hair grade‐2,total IgE \> 200 IU/ml   D11, 2 mg/kg/day
  8     F        8y9m    cough for 10 days, fever for 9 days             (--)                       1:320    unilateral centrilobular nodules, tree‐in‐bud and patchy shadow within the right lung   AR                                   mother AD                          mould grade‐2, total IgE \< 100 IU/ml                             no use

PE, physical examination; MP, *Mycoplasma pneumoniae*; HRCT, high resolution computer tomography; F, female; M, male; AD, allergic dermatitis; AR, allergic rhinitis; D, day.
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Clinical definition {#ped412108-sec-0010}
-------------------

An atopic background was defined as one of three findings: positive personal and/or family history of atopic disease, allergy to airborne allergens, or a history of atopic disease.

RESULTS {#ped412108-sec-0011}
=======

Demographic characteristics {#ped412108-sec-0012}
---------------------------

The eight patients in this study ranged in age from 3 years 10 months to 8 years 9 months (mean age: 6 years 1 month). Five patients were male and three were female.

Clinical features {#ped412108-sec-0013}
-----------------

All patients had a fever and cough for 3 to 14 days. Three patients had wheezing for 2 to 14 days. Moist rales and wheezing were noted in six patients.

Radiologic findings {#ped412108-sec-0014}
-------------------

Chest HRCT findings included centrilobular nodules, branching linear opacities (tree‐in‐bud pattern), and bronchiolar wall thickening (unilateral distribution in two patients \[Figure [1](#ped412108-fig-0001){ref-type="fig"}\] and bilateral distribution in six patients \[Figure [2](#ped412108-fig-0002){ref-type="fig"}\]). Focal bronchopneumonia was observed in six patients, and bronchial wall thickening and mucus plugs in two.

![Chest high resolution computer tomography scans of patient 8. (A, B) Unilateral centrilobular nodules, a tree‐in‐bud pattern, and a patchy shadow within the right lung were observed](PED4-2-248-g001){#ped412108-fig-0001}

![Chest high resolution computer tomography scans of patient 7. (A‐C) Bilateral and diffuse centrilobular nodules, a tree‐in‐bud pattern, and patchy shadows were observed](PED4-2-248-g002){#ped412108-fig-0002}

Co‐existing asthma and atopic background {#ped412108-sec-0015}
----------------------------------------

Two patients had asthma and two had allergic rhinitis before the onset of bronchiolitis. Seven patients had a personal and/or family history of atopic disease. Allergen testing was conducted in six patients, whereby four had positive results and two had negative results, although their total IgE levels were \> 200 IU/ml.

Treatment {#ped412108-sec-0016}
---------

All patients received azithromycin at a dose of 10 mg/kg/day for 5 days; this dose was repeated once more after an interval of 3 days. Six patients began treatment with 1 to 2 mg/kg/day of methylprednisolone on days 4, 9, 10, and 11 after the onset of illness, respectively. The total course ranged from 8 to 15 days in these patients. The remaining two patients (Patients 5 and 8) received a glucocorticoid via inhalation. One patient (Patient 1) developed respiratory failure and was given nasal continuous positive airway pressure ventilation. The remaining seven patients did not require supplemental oxygen therapy.

Follow‐up {#ped412108-sec-0017}
---------

All patients were followed up for 4 to 8 months. All were asymptomatic and had normal lung function and chest X‐rays at follow‐up.

DISCUSSION {#ped412108-sec-0018}
==========

We have herein reported the clinical features of childhood *M. pneumoniae* bronchiolitis. Although six patients had bronchopneumonia and two had large airway injury, the prominent findings on chest HRCT in all patients were in accordance with bronchiolitis (Figures [1](#ped412108-fig-0001){ref-type="fig"} and [2](#ped412108-fig-0002){ref-type="fig"}). Furthermore, all patients had evidence of *M. pneumoniae* infection. Therefore, the diagnosis of *M. pneumoniae* bronchiolitis was confirmed.

To the best of our knowledge, seven case reports and one case series of *M. pneumoniae* bronchiolitis have been published to date in the English‐language literature,[1](#ped412108-bib-0001){ref-type="ref"}, [3](#ped412108-bib-0003){ref-type="ref"}, [4](#ped412108-bib-0004){ref-type="ref"}, [5](#ped412108-bib-0005){ref-type="ref"}, [7](#ped412108-bib-0007){ref-type="ref"}, [8](#ped412108-bib-0008){ref-type="ref"}, [9](#ped412108-bib-0009){ref-type="ref"}, [10](#ped412108-bib-0010){ref-type="ref"} comprising nine adult cases and one pediatric case. In addition, Cha et al[11](#ped412108-bib-0011){ref-type="ref"} described 29 adult patients with *M. pneumoniae* infection, of whom eight had bronchiolitis (28%) and 21 had pneumonia. We conclude from these reports and our study that *M. pneumoniae* can cause bronchiolitis.

Why did *M. pneumoniae* infection cause bronchiolitis rather than airspace consolidation in these individuals? Tanaka[12](#ped412108-bib-0012){ref-type="ref"} found that the type of *M. pneumoniae* infection might be associated with host factors: in their study, upregulation of host cell‐mediated immunity predominantly caused centrilobular nodules, whereas downregulation of host cell‐mediated immunity changed the radiological pattern to consolidation. We propose that *M. pneumoniae* bronchiolitis might be associated with an atopic constitution because all patients in this study had atopic backgrounds. Vasudevan et al[7](#ped412108-bib-0007){ref-type="ref"} reported that an adult with severe *M. pneumoniae* bronchiolitis had a history of asthma; moreover, Kawamoto et al[8](#ped412108-bib-0008){ref-type="ref"} found elevated levels of eosinophil cationic protein and IgE in two patients with *M. pneumoniae* bronchiolitis, further supporting the hypothesis that atopy may be associated with the occurrence of *M. pneumoniae* bronchiolitis.

Our previous study[2](#ped412108-bib-0002){ref-type="ref"} and other reports[3](#ped412108-bib-0003){ref-type="ref"}, [4](#ped412108-bib-0004){ref-type="ref"}, [5](#ped412108-bib-0005){ref-type="ref"} have shown that BO can develop following acute *M. pneumoniae* bronchiolitis. Because BO is a chronic airway obstruction disease and is irreversible, it is important to prevent the development of BO after acute *M. pneumoniae* bronchiolitis.

BO is caused by granulation tissue obstruction, and glucocorticoids can inhibit the formation of granulation tissue. In our previous study, 17 patients with acute *M. pneumoniae* bronchiolitis developed BO soon after acute *M. pneumoniae* bronchiolitis, and only 10 (59%) of them received systemic glucocorticoid therapy.[2](#ped412108-bib-0002){ref-type="ref"} Therefore, we speculate that glucocorticoids might have a beneficial effect on preventing the development of BO after acute *M. pneumoniae* bronchiolitis. Additionally, because the features of BO on HRCT, such as pronounced air‐trapping and a mosaic pattern, were noted within 2 to 3 weeks following the onset of bronchiolitis,[2](#ped412108-bib-0002){ref-type="ref"} we surmise that initiation of glucocorticoids within 2 weeks might play a preventive role. However, the appropriate time window for starting glucocorticoids and for how long they may be used require further study.

To explore the effect of glucocorticoid thera py on preventing the development of BO after acute *M. pneumoniae* bronchiolitis, we treated six patients (75%) in this study with 1 to 2 mg/kg/day of methylprednisolone after admission at 9.2 ± 2.3 days after onset of acute *M. pneumoniae* bronchiolitis, as shown in Table [1](#ped412108-tbl-0001){ref-type="table"}. Compared with the 10 patients who developed BO and received 1 to 2 mg/kg/day of methylprednisolone at 12.2 ± 3.5 days as reported in our previous study,[2](#ped412108-bib-0002){ref-type="ref"} the time of glucocorticoid initiation in these six patients was 3 days earlier (9.2 ± 2.3 versus 12.2 ± 3.5 days). The remaining two mildly affected patients received a glucocorticoid via inhalation. The fact that none of our eight patients developed BO supports the notion that earlier initiation of glucocorticoid therapy might favor the prognosis of acute *M. pneumoniae* bronchiolitis.

This study has some limitations. Because acute bronchiolitis caused by *M. pneumoniae* is rare, the patient sample was too small to support a definitive conclusion. However, given that BO has such a harmful influence on children\'s quality of life and acute *M. pneumoniae* bronchiolitis is not widely encountered, this study carries some significance. The utilization, time of initiation, and effects of glucocorticoids administration in the prevention of BO development warrant further investigation.

*M. pneumoniae* bronchiolitis can occur in children, especially in atopic individuals. T he use, time of initiation, and effects of glucocorticoids administration in these patients for the prevention of BO require further investigation.
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